Old Web
English
Sign In
Acemap
>
authorDetail
>
Zhengning Lin
Zhengning Lin
BioMarin Pharmaceutical
Duchenne muscular dystrophy
Placebo
Drisapersen
Adverse effect
Phases of clinical research
2
Papers
79
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy
2018
Annals of clinical and translational neurology
Craig M. McDonald
Brenda Wong
Kevin M. Flanigan
Rosamund Wilson
Sjef J. de Kimpe
Afrodite Lourbakos
Zhengning Lin
G. Campion
Show All
Source
Cite
Save
Citations (15)
A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
2018
Neuromuscular Disorders
Nathalie Goemans
Eugenio Mercuri
Elena Belousova
Hirofumi Komaki
Alberto Dubrovsky
Craig M. McDonald
John E. Kraus
A. Lourbakos
Zhengning Lin
G. Campion
Susanne X. Wang
Craig Campbell
Show All
Source
Cite
Save
Citations (64)
1